These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35612854)

  • 1. Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.
    Teoh D; Nam G; Aase DA; Russell R; Melton GB; Kulasingam S; Vogel RI
    JAMA Netw Open; 2022 May; 5(5):e2214020. PubMed ID: 35612854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
    Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
    Beecroft M; Gurumurthy M; Cruickshank ME
    BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
    Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
    JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
    Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Cotton S; Nicoll S; Robertson C
    Br J Cancer; 2016 Mar; 114(5):582-9. PubMed ID: 26931370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of high-risk human papillomavirus testing in the triage of abnormal cervical cytology among Chinese younger women in Shanghai, China.
    Jiang L; Zeng Y; Li J; Wang H; Xia Y; Fang X; Zhang P
    Asian Pac J Cancer Prev; 2011; 12(11):2963-7. PubMed ID: 22393972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
    Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
    J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
    Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
    Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
    Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
    Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.